Progyny CEO Peter Anevski sells $8.48 million in company stock

The transaction involved 185,134 shares valued at about $6,636,065 and an additional 51,496 shares for approximately $1,845,853. These shares were sold at prices ranging from $35.00 to $36.43.

The sales were executed under a pre-arranged Rule 10b5-1 trading plan, a common strategy for corporate insiders to sell shares at predetermined times and prices. This plan was established prior to any knowledge of material non-public information.

The stock sale follows Mr. Anevski’s acquisition of 185,134 shares through the exercise of fully vested stock options at a price of $0.91 per share.

Strong earnings and analyst upgrades

Progyny’s shares are trading near their 52-week high of $37.16, reflecting a 49.8% return over the past year. The company reported third-quarter 2026 earnings that exceeded Wall Street expectations, with adjusted earnings per share of $0.32 compared to a forecast of $0.3126.

The company also announced a record-breaking selling season, adding 1.3 million new covered lives and over 85 new clients. Following these developments, Progyny raised its full-year outlook, drawing attention from investors.

Wells Fargo also adjusted its price target for Progyny shares to $38 from $37, maintaining an Overweight rating. The firm highlighted a 16% growth in covered lives and noted improving usage trends.